Dear Voornaam,

In 2019, Ed Tate, Roberto Solari and Andrew Bell founded Myricx Bio to discover and develop a completely novel class of antibody-drug conjugates (ADCs), based on their CRUK-funded research into N-myristoyltransferase (NMT).

Less than five years later, Myricx closed its Series A financing round after raising £90m, including investment from Cancer Research Horizons.

The team’s breakthrough was discovering the potential of NMT inhibitors to treat cancer and they have since demonstrated their efficacy as a completely new class of ADC. Currently, over 90% of clinical ADCs are based on only three mechanisms. Diversifying the pipeline will offer more treatment options to people who respond poorly to well-known payloads.

Success in Boston, next stop London – save the date for our Cancer Prevention Research Conference

The second annual Cancer Prevention Research Conference is taking place in London from 25–27 June 2025. This follows the sold out first event in Boston where over 350 attendees from all over the world had the opportunity to engage and discuss the latest concepts in cancer prevention research.

This year’s event will be hosted by Cancer Research UK, in collaboration with the American Cancer Society. Mark the date in your calendars and register your interest to be amongst the first to hear when registrations open.